GlassScriptPhysician profile
Sandhya R Bogi
NPI 1306167788
$1,976.21
in general payments reported to CMS, 2019-2025
28 companies · $806 in 2025
The $806 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $110 · 2021: $245 · 2022: $127 · 2023: $271 · 2024: $288 · 2025: $806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,341.64 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $441.64 | 2019-2023 | |
| Medtronic, INC. | $181.97 | 2025 | Simplera Sensor, Minimed 780g |
| Janssen Pharmaceuticals, INC | $143.11 | 2022-2024 | Xarelto |
| Amgen INC. | $139.23 | 2024-2025 | Evenity, Prolia, Tepezza |
| Abbvie INC. | $123.72 | 2021-2025 | |
| Beta Bionics, INC. | $114.36 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Novo Nordisk INC | $103.53 | 2025 | Wegovy, Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $99.95 | 2020-2023 | Eliquis |
| Neurocrine Biosciences, INC. | $72.89 | 2024-2025 | |
| Corcept Therapeutics | $62.00 | 2024-2025 | Korlym |
| Inari Medical, INC. | $53.86 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Lilly USA, LLC | $50.92 | 2024-2025 | Mounjaro, Zepbound |
| Kyowa Kirin, INC. | $49.43 | 2024 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.78 | 2022-2023 | Jardiance, Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $34.46 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $31.98 | 2024 | Ultomiris |
| Tandem Diabetes Care, INC. | $27.69 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $24.46 | 2025 | Freestyle Libre 3 |
| Rhythm Pharmaceuticals, INC. | $23.58 | 2025 | Imcivree |
| Recordati_rare_diseases_inc. | $22.99 | 2025 | Isturisa |
| Sequel Med Tech, LLC | $22.52 | 2025 | Twiist |
| Chiesi USA, INC. | $20.41 | 2025 | Mycapssa |
| Xeris Pharmaceuticals, INC. | $20.22 | 2025 | Recorlev |
| Merck Sharp & Dohme LLC | $19.21 | 2022 | |
| Ascendis Pharma Endocrinology INC | $17.61 | 2025 | Yorvipath |
| Scpharmaceuticals INC. | $13.55 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.34 | 2020 | |
| Allergan, INC. | $11.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandhya Bogi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.